Literature DB >> 4275944

Ultrastructural, immunologic, and functional studies on Sézary cells: a neoplastic variant of thymus-derived (T) lymphocytes.

D Zucker-Franklin, J W Melton, F Quagliata.   

Abstract

The vast majority of human lymphoid neoplasms examined to date have been associated with a proliferation of bone marrow-dependent (B) lymphocytes. In an effort to delineate human tumors of T-cell (thymusdependent) lineage, use was made of the peripheral blood leukocytes of sixteen subjects with various forms of mycosis fungoides. The abnormal cells in the circulation of these patients are morphologically identical to those that infiltrate their nodes and skin. On electron microscopy, such neoplastic lymphocytes (Sézary cells) had "cerebriform" nuclei and an abundance of cytoplasmic fibrils not described heretofore. Sézary cells were nonadherent and nonphagocytic and usually responded to stimulation with phytohemagglutinin, refuting earlier suggestions that the cells represent monocytes or histiocytes. In contrast to chronic lymphocytic leukemia lymphocytes, the Sézary cells lacked surface immunoglobulin and receptors for complement. Ultrastructural analysis identified Sézary cells in the center of directly formed rosettes (E-rosettes) characterizing the behavior of T lymphocytes in this test. Though some Sézary cells lacked both T and B cell-surface properties, in general, these observations support the view that the Sézary cell is a neoplastic variant of a thymusderived lymphocyte.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4275944      PMCID: PMC388345          DOI: 10.1073/pnas.71.5.1877

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  The ultrastructure of an abnormal cell in Sézary's syndrome.

Authors:  M A Lutzner; H W Jordan
Journal:  Blood       Date:  1968-06       Impact factor: 22.113

2.  The Sézary syndrome: cytogenetic studies and identification of the Sézary Cell as an abnormal lymphocyte.

Authors:  P E Crossen; J E Mellor; A G Finley; R B Ravich; P C Vincent; F W Gunz
Journal:  Am J Med       Date:  1971-01       Impact factor: 4.965

3.  Ultrastructure of abnormal cells in Sezary syndrome, mycosis fungoides, and parapsoriasis en plaque.

Authors:  M A Lutzner; J W Hobbs; P Horvath
Journal:  Arch Dermatol       Date:  1971-04

4.  Binding of sheep red blood cells to a large population of human lymphocytes.

Authors:  W H Lay; N F Mendes; C Bianco; V Nussenzweig
Journal:  Nature       Date:  1971-04-23       Impact factor: 49.962

5.  Ultrastructure of mycosis fungoides.

Authors:  T R Brownlee; T M Murad
Journal:  Cancer       Date:  1970-09       Impact factor: 6.860

6.  Intracellular localization of human amyloid by fluorescence and electron microscopy.

Authors:  D Zucker-Franklin; E C Franklin
Journal:  Am J Pathol       Date:  1970-04       Impact factor: 4.307

7.  Chromosome studies in chronic lymphocytic leukemia and lymphosarcoma.

Authors:  P H Fitzgerald; A Adams
Journal:  J Natl Cancer Inst       Date:  1965-06       Impact factor: 13.506

8.  Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia.

Authors:  H M Grey; E Rabellino; B Pirofsky
Journal:  J Clin Invest       Date:  1971-11       Impact factor: 14.808

9.  Dissociation of hemolytic and lymphocyte-transforming activities of streptolysin S preparations.

Authors:  A Taranta; G Cuppari; F Quagliata
Journal:  J Exp Med       Date:  1969-04-01       Impact factor: 14.307

10.  A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization.

Authors:  C Bianco; R Patrick; V Nussenzweig
Journal:  J Exp Med       Date:  1970-10-01       Impact factor: 14.307

View more
  21 in total

1.  T-cell specific microenvironment in mycosis fungoides.

Authors:  M Goos
Journal:  Arch Dermatol Res       Date:  1976-04-21       Impact factor: 3.017

2.  Evidence for the presence of a receptor for IgM on the pathological cells of Sézary's syndrome.

Authors:  C P Worman; G F Burns; C R Barker
Journal:  Clin Exp Immunol       Date:  1978-03       Impact factor: 4.330

3.  Transmission of human T-cell lymphotropic virus type 1 tax to rabbits by tax-only-positive human cells.

Authors:  D Zucker-Franklin; B A Pancake; P Lalezari; M Khorshidi
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 4.  Malignant lymphomas--a conceptual understanding of morphologic diversity. A review.

Authors:  R B Mann; E S Jaffe; C W Berard
Journal:  Am J Pathol       Date:  1979-01       Impact factor: 4.307

5.  Characterization of non-Hodgkin's lymphomas using multiple cell markers. Immunologic, morphologic, and cytochemical studies of 72 cases.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1979-02       Impact factor: 4.307

6.  T-cell nature of leukaemic cells in a case of Sézary's syndrome with 'null-cell' features.

Authors:  L Lauriola; P Musiani; A Carbone; M Bartolini; P Cianciulli; M Piantelli
Journal:  J Clin Pathol       Date:  1979-09       Impact factor: 3.411

7.  Immunoblastic sarcoma with leukemic blood picture in the terminal stage of mycosis fungoides.

Authors:  E W Schwarze; P Ude
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975-12-31

8.  [Cerebral involvement in the Sézary syndrome (author's transl)].

Authors:  F Gerstenbrand; K Jellinger; D Lutz; E Maida
Journal:  J Neurol       Date:  1976-03-23       Impact factor: 4.849

9.  Chronic lymphocytic leukemia cells lack the 185,000-dalton macromolecular insoluble cold globulin present on normal B lymphocytes.

Authors:  M A Simmonds; G Sobczak; S P Hauptman
Journal:  J Clin Invest       Date:  1981-03       Impact factor: 14.808

10.  Detection of human T-lymphotropic virus-like particles in cultures of peripheral blood lymphocytes from patients with mycosis fungoides.

Authors:  D Zucker-Franklin; E E Coutavas; M G Rush; D C Zouzias
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.